MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1)

Wen Xie, Kaihong Su, Dongyan Wang, Andrew J. Paterson, Jeffrey E. Kudlow

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Epidermal growth factor (EGF) usually stimulates the proliferation of a variety of normal and malignant cells. In contrast, MDA468, a human breast cancer cell line with a very high number of EGF receptors, is growth inhibited in response to concentrations of EGF that stimulate most other cells. The purpose of this study was to elucidate the cellular mechanisms involved in EGF-induced growth inhibition. EGF treatment stimulated the sustained expression of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1). The p21(WAF1) induction in EGF-treated MDA468 cells is probably p53-independent since these cells contain no active p53. The promoter for p21(WAF1) gene contains binding sites for signal transducer and activator of transcription (STAT) and EGF is known to activate members of this family of transcription factors. Using electrophoretic mobility shift assays (EMSA), we found that EGF activates STAT1 and STAT3 in the MDA468 cells. These activated STATs specifically recognised the three conserved STAT- responsive elements in the p21(WAF1) gene promoter, suggesting that STATs may be responsible for the p21(WAF1) induction by EGF in MDA468 cells. The sustained rise in p21(WAF1) in response to EGF is proposed to be a means of growth inhibition in these cells.

Original languageEnglish (US)
Pages (from-to)2627-2633
Number of pages7
JournalAnticancer Research
Volume17
Issue number4 A
StatePublished - Sep 3 1997

Fingerprint

Cyclin-Dependent Kinase Inhibitor p21
Epidermal Growth Factor
Growth
Transducers
Inhibition (Psychology)
Electrophoretic Mobility Shift Assay
Genes
Transcription Factors
Binding Sites
Breast Neoplasms
Cell Line

Keywords

  • Epidermal growth factor
  • Growth inhibition
  • MDA468 cells
  • P21(WAF1)
  • STATs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Xie, W., Su, K., Wang, D., Paterson, A. J., & Kudlow, J. E. (1997). MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1). Anticancer Research, 17(4 A), 2627-2633.

MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1). / Xie, Wen; Su, Kaihong; Wang, Dongyan; Paterson, Andrew J.; Kudlow, Jeffrey E.

In: Anticancer Research, Vol. 17, No. 4 A, 03.09.1997, p. 2627-2633.

Research output: Contribution to journalArticle

Xie, W, Su, K, Wang, D, Paterson, AJ & Kudlow, JE 1997, 'MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1)', Anticancer Research, vol. 17, no. 4 A, pp. 2627-2633.
Xie, Wen ; Su, Kaihong ; Wang, Dongyan ; Paterson, Andrew J. ; Kudlow, Jeffrey E. / MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1). In: Anticancer Research. 1997 ; Vol. 17, No. 4 A. pp. 2627-2633.
@article{a7834cfa73c64c5184b73fdf9b08f4d8,
title = "MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1)",
abstract = "Epidermal growth factor (EGF) usually stimulates the proliferation of a variety of normal and malignant cells. In contrast, MDA468, a human breast cancer cell line with a very high number of EGF receptors, is growth inhibited in response to concentrations of EGF that stimulate most other cells. The purpose of this study was to elucidate the cellular mechanisms involved in EGF-induced growth inhibition. EGF treatment stimulated the sustained expression of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1). The p21(WAF1) induction in EGF-treated MDA468 cells is probably p53-independent since these cells contain no active p53. The promoter for p21(WAF1) gene contains binding sites for signal transducer and activator of transcription (STAT) and EGF is known to activate members of this family of transcription factors. Using electrophoretic mobility shift assays (EMSA), we found that EGF activates STAT1 and STAT3 in the MDA468 cells. These activated STATs specifically recognised the three conserved STAT- responsive elements in the p21(WAF1) gene promoter, suggesting that STATs may be responsible for the p21(WAF1) induction by EGF in MDA468 cells. The sustained rise in p21(WAF1) in response to EGF is proposed to be a means of growth inhibition in these cells.",
keywords = "Epidermal growth factor, Growth inhibition, MDA468 cells, P21(WAF1), STATs",
author = "Wen Xie and Kaihong Su and Dongyan Wang and Paterson, {Andrew J.} and Kudlow, {Jeffrey E.}",
year = "1997",
month = "9",
day = "3",
language = "English (US)",
volume = "17",
pages = "2627--2633",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 A",

}

TY - JOUR

T1 - MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21(WAF1)

AU - Xie, Wen

AU - Su, Kaihong

AU - Wang, Dongyan

AU - Paterson, Andrew J.

AU - Kudlow, Jeffrey E.

PY - 1997/9/3

Y1 - 1997/9/3

N2 - Epidermal growth factor (EGF) usually stimulates the proliferation of a variety of normal and malignant cells. In contrast, MDA468, a human breast cancer cell line with a very high number of EGF receptors, is growth inhibited in response to concentrations of EGF that stimulate most other cells. The purpose of this study was to elucidate the cellular mechanisms involved in EGF-induced growth inhibition. EGF treatment stimulated the sustained expression of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1). The p21(WAF1) induction in EGF-treated MDA468 cells is probably p53-independent since these cells contain no active p53. The promoter for p21(WAF1) gene contains binding sites for signal transducer and activator of transcription (STAT) and EGF is known to activate members of this family of transcription factors. Using electrophoretic mobility shift assays (EMSA), we found that EGF activates STAT1 and STAT3 in the MDA468 cells. These activated STATs specifically recognised the three conserved STAT- responsive elements in the p21(WAF1) gene promoter, suggesting that STATs may be responsible for the p21(WAF1) induction by EGF in MDA468 cells. The sustained rise in p21(WAF1) in response to EGF is proposed to be a means of growth inhibition in these cells.

AB - Epidermal growth factor (EGF) usually stimulates the proliferation of a variety of normal and malignant cells. In contrast, MDA468, a human breast cancer cell line with a very high number of EGF receptors, is growth inhibited in response to concentrations of EGF that stimulate most other cells. The purpose of this study was to elucidate the cellular mechanisms involved in EGF-induced growth inhibition. EGF treatment stimulated the sustained expression of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1). The p21(WAF1) induction in EGF-treated MDA468 cells is probably p53-independent since these cells contain no active p53. The promoter for p21(WAF1) gene contains binding sites for signal transducer and activator of transcription (STAT) and EGF is known to activate members of this family of transcription factors. Using electrophoretic mobility shift assays (EMSA), we found that EGF activates STAT1 and STAT3 in the MDA468 cells. These activated STATs specifically recognised the three conserved STAT- responsive elements in the p21(WAF1) gene promoter, suggesting that STATs may be responsible for the p21(WAF1) induction by EGF in MDA468 cells. The sustained rise in p21(WAF1) in response to EGF is proposed to be a means of growth inhibition in these cells.

KW - Epidermal growth factor

KW - Growth inhibition

KW - MDA468 cells

KW - P21(WAF1)

KW - STATs

UR - http://www.scopus.com/inward/record.url?scp=0030792410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030792410&partnerID=8YFLogxK

M3 - Article

C2 - 9252692

AN - SCOPUS:0030792410

VL - 17

SP - 2627

EP - 2633

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 A

ER -